Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Procter & Gamble Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Procter & Gamble Co trades at $146.1 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 42.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Procter & Gamble Co pays a 2.92% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PG | |
|---|---|---|
Market Cap | $8.04B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $167.18 |
52-Week Low | $241.71 | $138.10 |
Enterprise Value | $7.85B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Procter & Gamble (PG) trades at $148.37, up 0.9% on the day, with a neutral technical signal and bullish moving averages. The stock shows stable revenue near $84.3 billion in 2025 and consistent earnings beats, with a net income margin of 19.16%. Recent news highlights its dividend reliability amid market volatility, while analyst consensus leans bullish with a $161.71 price target.
PG offers steady growth and income appeal, supported by strong cash flow and a 69-year dividend growth streak. Risks include premium valuation multiples and soft demand concerns. Upside depends on execution of supply chain efficiencies and sustained margin strength in a competitive consumer staples landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
